Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Lymphoma, B-Cell 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 16fludarabine 12Rituximab 4Antigens, CD19 4Lenalidomide 3Immunotherapy, Adoptive 3Etoposide 3orelabrutinib 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Methotrexate 2zanubrutinib 1relmacabtagene autoleucel 1prednylidene 1obinutuzumab 1merphos 1ixazomib 1gemcitabine-oxaliplatin regimen 1fludarabine phosphate 1entecavir 1eltrombopag 1deltacortene 1abivertinib 1Vincristine 1Transplantation, Autologous 1Tenofovir 1Prednisone 1Pentostatin 1Melphalan 1Interleukin-7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, B-Cell × gemcitabine-oxaliplatin regimen × Clear all
NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡